BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SKB575 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SKB575\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07488065-3683@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SKB575: Phase 1 readout est. (NCT07488065)
DESCRIPTION:SKB575\, phase 1\, Atopic Dermatitis.\nStudy: A Study of SKB575
  (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Partici
 pants\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/skb575#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07488065
URL:https://assetmemo.bio/drug/skb575#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732023-3683@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:SKB575: Phase 1 readout est. (NCT07732023)
DESCRIPTION:SKB575\, phase 1\, Asthma.\nStudy: A Randomized\, Phase Ib\, Do
 uble-Blind\, Placebo-Controlled Study to Evaluate the Safety and Efficacy 
 of SKB575 (HBM7575) in Participants With Asthma\nEstimated primary complet
 ion: 30 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sk
 b575#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07732023
URL:https://assetmemo.bio/drug/skb575#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
